Home THIS WEBSITE IS INTENDED FOR HEALTHCARE PROFESSIONALS (HCPs) ONLY

Sylvant logo Menu

iMCD: The spectrum of disease and clinical behaviour - Challenges of long-term management

James Cavet, Consultant Haematologist discusses long-term maintenance to reduce the risk of iMCD flares.

DosingRecommended dosing of SYLVANT®:1

Use aseptic technique for reconstitution and preparation of dosing solution.1

Once reconstituted, SYLVANT® should not be kept for more than 2 hours prior to the addition to the infusion bag.1

The infusion should be completed within 6 hours of the addition of the reconstituted solution to the infusion bag.1

The patient should have a blood test before each dose of SYLVANT® for the first 12 months and every third dosing cycle thereafter.1 Consider delaying treatment if the following criteria are not met (dose reduction is not recommended).


Dosing

Delay treatment if the patient has a severe infection or any severe non-haematological toxicity – SYLVANT® can be restarted at the same dose after recovery.

Discontinue further SYLVANT® treatment if the patient develops:1

Consider discontinuing SYLVANT® if there are more than 2 dose delays due to toxicities related to the treatment during the first 48 weeks.

Special populations – please refer to the full EU SmPC1 for further details.

References
1. SYLVANT® EU Summary of Product Characteristics (2019).